Skip to main content

FTC Urges On No Delay In JUUL & Altria Trial

FTC Urges On No Delay In JUUL & Altria Trial

FTC Urges On No Delay In JUUL & Altria Trial

Introduction

Federal Trade Commission’s (FTC) trial staff has urged that the commission should not delay the virtual trial slated for April 13 against the tobacco manufacturer Altria's $12.8 billion investment in electronic cigarette company Juul.

Juul Labs Inc. and Altria Group Inc are demanding to delay the trial further from the current date of April 13 to mid-July, considering the worsening pandemic outbreak. The FTC's trial staff is opposing both the company's demands by stating that it is unrealistic speculation that holding an in-person trial in mid-July will be safe. FTC's complaint counsel said that the proceedings should begin virtually at the start of mid-April and keep the proceedings virtual. 

The staffers informed that although the vaccine news is promising, it is not clear if the chief administrative law judge and his staff, witnesses, and counsel will get the vaccination any soon, making it better to conduct virtual hearings for the case.

The attorneys for the companies argued that the trial should be delayed further, as the masses will not get the vaccine until late June or early July. They even informed that starting virtual hearings will not prevent the health risk, as the attorneys will require to plan accordingly by gathering in-person evidence and prepare witnesses. The attorneys even raised concern over the credibility of the testifying witnesses.

The Federal Trade Commission is overseeing the case, In the Matter of Altria Group/Juul Labs, file number 191-0075.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!